Clinical trials: Rabies Virus Infection
Rabies Post-exposure Prophylaxis
Study to Evaluate GR1801's Efficacy and Safety
The goal of this clinical trial is to compare the efficacy and safety of GR1801 injection with Human Rabies Immunoglobulin(HRIG) in patients with WHO Category 3 rabies exposure. Patients will receive GR1801 injection or HRIG.
- Trial name
- NCT05846568
- Testing
- GR1801, Human Rabies Immunoglobulin(HRIG), Rabies Vaccine
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Rabies
Efficacy and Safety of a PIKA Rabies Vaccine Containing the PIKA Adjuvant With an Accelerated Regimen
Phase II clinical study for an investigational PIKA(Polyinosinic Polycytidylic Acid Based Adjuvant) rabies vaccine comprising Inactivated and Purified Rabies Virus (IPRV) and the PIKA adjuvant.
- Trial name
- NCT02956421
- Testing
- RABIPUR®, PIKA rabies vaccine
- Where
- 2 sites in Singapore
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Yisheng Biopharma (Singapore) Pte. Ltd.
Rabies
Safety and Tolerability of CV8102 Alone and in Combination With a Rabies Virus Vaccine in Healthy Adults
The purpose of this clinical trial is to investigate the safety and tolerability of IM administered CV8102 and an IM administered combination of CV8102 and rabies vaccine in humans.
- Trial name
- NCT02238756
- Testing
- CV8102, Rabipur, CV8102 + Rabipur
- Where
- Germany
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- CureVac
Rabies (Healthy Volunteers)
Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adults in Thaïland
Primary Objective: To describe the immune response induced by VRVg-2 and Verorab vaccines at D14 and D35 when co-administered with Human Rabies Immunoglobulins (HRIG) at D0, according to the Zagreb (2-1-1) IM regimen in healthy…
- Trial name
- NCT04594551
- Testing
- Purified vero rabies vaccine - serum free, Purified inactivated rabies vaccine, Human rabies immunoglobulins
- Where
- 3 sites in Thailand
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Rabies (Healthy Volunteers)
A Phase II Trial of a Recombinant Human Anti-Rabies Virus Monoclonal Antibody
A Phase II, Single-Center, Randomized, Blinded, Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacodynamics of a Recombinant Human Anti-Rabies Virus Monoclonal Antibody Injection in Healthy Subjects
- Trial name
- NCT07445815
- Testing
- Recombinant Human Rabies Virus Monoclonal Antibody Injection, Human Rabies Immunoglobulin (HRIG), Rabies Vaccine
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Lanzhou Institute of Biological Products Co., Ltd
Rabies
Study of Purified Vero Rabies Vaccine and Rabies Human Diploid Cell Vaccine in a Simulated Rabies Post-exposure Regimen
The aim of the study is to document the safety and immunogenicity of Purified Vero Rabies Vaccine (VRVg) when given in a simulated post-exposure regimen, i.e.
- Trial name
- NCT01877395
- Testing
- Purified Vero Rabies Vaccine (VRVg), Imovax® Rabies: inactivated rabies vaccine
- Where
- 5 sites in United States
- Volunteers
- 342 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Rabies
Comparison of Purified Vero Rabies Vaccine, Serum Free With Human Diploid Cell Vaccine in Pre-exposure Use
The aim of this study is to generate data on immunogenicity and safety of Purified Vero Rabies Vaccine - Serum Free (VRVg) in comparison with Imovax® Rabies in order to support the registration of VRVg in the USA.
- Trial name
- NCT01784874
- Testing
- Purified Vero Rabies Vaccine (VRVg) - Serum Free, Imovax® Rabies: inactivated rabies vaccine
- Where
- 6 sites in United States
- Volunteers
- 408 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Rabies Virus Infection
Rabies mAb CBB 1 Combination Vaccine in Healthy People With Antibody Neutralization Activity and Safety Phase Clinical Trials
To evaluate the antibody neutralization activity and safety of rabies mAb CBB 1 combination vaccine used in healthy people
- Trial name
- NCT06548139
- Testing
- Natural full human monoclonal antibody CBB 1 injection 50.0µg/kg, Natural full human monoclonal antibody CBB 1 injection 100.0µg/kg, Rabies Human Immunoglobulin (HRIG)
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Changchun BCHT Biotechnology Co.
Rabies
Comparison of SYN023 to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies
This is a Phase 2b, double blinded, randomized study of SYN023 compared to HyperRab® (a licensed Rabies immune globulin from human sources, HRIG) for the prevention of rabies as part of post-exposure prophylaxis (PEP).
- Trial name
- ARPEP (NCT03961555)
- Testing
- SYN023, HRIG (HyperRab), Rabies vaccine
- Where
- 14 sites in United States, Philippines
- Volunteers
- 448 people
- Sponsor
- Synermore Biologics Co., Ltd.
Rabies Human
To Evaluate the Immunogenicity and Safety of Two Different Immunization Schedules of Rabies Vaccine (Vero Cell)
To evaluate the safety and immunogenicity of lyophilized human rabies vaccine (Vero cell) developed by Hualan Biological in healthy people aged 9 to 65 years with two different immunization schedules.
- Trial name
- rabies (NCT06177249)
- Testing
- Control vaccine, Experimental vaccine
- Where
- China
- Volunteers
- 1,956 people, healthy volunteers welcome
- Sponsor
- Hualan Biological Bacterin Co. Ltd.
Rabies
Single Center, Open Label, Follow up Study in Subjects Who Previously Received Rabies Vaccine as Simulated Post-Exposure Regimen
This study will evaluate the immunogenicity of rabies vaccine at 13 months, 3 year and 5 years after initial vaccination, administered in two different post-exposure vaccination schedules
- Trial name
- NCT01067079
- Testing
- No vaccine administered; subjects only have blood sampling for immunogenicity
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Rabies
Randomized Phase II Trial on Safety and Neutralizing Activity of CL184 and Rabies Vaccine Versus Human Rabies Immune Globulin (HRIG) and Rabies Vaccine in Children and Adolescents
The aim of this study is to evaluate the safety of the monoclonal antibody cocktail CL184 in combination with rabies vaccine compared with human rabies immune globulin (HRIG) in combination with rabies vaccine in healthy children…
- Trial name
- NCT00708084
- Testing
- CL184, HRIG
- Where
- Philippines
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Virus Diseases, Rabies
A Phase 3 Clinical Trial to Evaluate Long-term Immunogenicity and Boostability of Purified Chick-Embryo Cell Rabies Vaccine in Adults Following Primary Series of Pre/Exposure Prophylaxis.
The aim of this study is to evaluate the long-term (up to approx.10 years) persistence and to assess the boostability of immune responses in participants who received a primary series of accelerated or conventional rabies PrEP IM…
- Trial name
- NCT02545517
- Testing
- Rabipur, Blood sampling, Purified Chick-Embryo Cell Rabies Vaccine
- Where
- 7 sites in Austria, Germany and 1 more
- Volunteers
- 459 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Virus Diseases
A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Experimental Rabies Vaccine in Healthy Adults
The purpose of this first time-in-human (FTiH) study is to evaluate the safety, reactogenicity and immunogenicity of different dose levels of an experimental rabies glycoprotein G (RG) vaccine (RG-SAM [CNE] vaccine), made using a…
- Trial name
- NCT04062669
- Testing
- Low dose formulation of RG SAM (CNE) vaccine (GSK3903133A), Medium dose formulation of RG SAM (CNE) vaccine (GSK3903133A), Lower dose formulation of RG SAM (CNE) vaccine (GSK3903133A)
- Where
- 4 sites in United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Virus Diseases
A Study to Evaluate Persistence of Immune Responses After Post-exposure Prophylaxis of Rabipur® (Purified Chicken-embryo Cell Rabies Vaccine) in Chinese Children
The purpose of this study is to evaluate the long-term persistence of immune responses approximately 5 years or more after simulated rabies post-exposure prophylaxis provided in 2012 according to Essen (1-1-1-1-1) or Zagreb…
- Trial name
- NCT02991872
- Testing
- Blood draw
- Where
- China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Rabies, Rabies Virus
Study of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Reference Purified Vero Rabies Vaccine
This study is designed to gather safety and immunogenicity data with Purified Vero Rabies Vaccine - Serum Free (VRVg), when given in a post-exposure prophylaxis vaccination schedule, using the Essen regimen, across different…
- Trial name
- NCT01339312
- Testing
- Purified inactivated rabies vaccine, serum free, Purified Vero Rabies Vaccine
- Where
- China
- Volunteers
- 816 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Rabies
Immunogenicity and Safety of Verorab® in a "One-week" Intradermal Post-exposure Prophylaxis Regimen
The purpose of this study is to assess the 4-site "one-week" post-exposure prophylaxis (PEP) regimen as a possible alternative to the 2-site updated Thai Red Cross (TRC) PEP regimen.
- Trial name
- NCT01622062
- Testing
- PVRV, PVRV and pERIG Favirab®
- Where
- Philippines
- Volunteers
- 600 people
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Virus Diseases
A Study to Evaluate the One Year Long-term Persistence of Immune Responses Following Two Different Rabies Vaccine Post-exposure Regimens in Chinese Children
The purpose of this study is to evaluate the 1 year immunogenicity persistence of Rabipur in children 6-17 years of age, and compare the Zagreb regimen with the Essen regimen.
- Trial name
- NCT03192371
- Testing
- Rabipur
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Rabies, Healthy Volunteers
Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines, Given in a Pre-exposure Regimen to Children and Adults and as Single Booster Dose to a Subset of Adults
The primary objective of this study is: To demonstrate the VRVg-2 is non-inferior to Verorab and Imovax Rabies vaccines in each age group (pediatric and adult populations) when administered as a 3-dose PrEP regimen, in terms of…
- Trial name
- VRV12 (NCT04127786)
- Testing
- Purified vero rabies vaccine - serum free - VRVg-2, Purified inactivated rabies vaccine - Verorab®, Purified inactivated rabies vaccine - Imovax® Rabies
- Where
- 4 sites in Thailand
- Volunteers
- 1,708 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Rabies
A Clinical Trial of Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried
The Phase 1 clinical trial of the freeze-dried human rabies vaccine (human diploid cells) will be conducted on participants aged 10 to 60.
- Trial name
- NCT07021703
- Testing
- Freeze-dried Human Rabies Vaccine（Human Diploid Cell）, Essen, Freeze-dried Human Rabies Vaccine（Human Diploid Cell），Zagreb
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Ningbo Rongan Biological Pharmaceutical Co., Ltd.